Skip to main content
Caplight Logo









WebenPharma

WebenPharma

Private
HangzhouHealthcare & Life Scienceshttp://webenpharma.com/

Last Round

Angel

Jan 28, 2022

Company Overview

WebenPharma operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was an Angel round in January 2022.

WebenPharma is a biopharmaceutical company that focuses on the discovery, development, and commercialization of targeted small molecule drugs to treat cancer patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

WebenPharma Comparables

Compare WebenPharma with similar companies based on industry and business-model similarity.

WebenPharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MycRx
88%
Incurix
82%
RDP Pharma AG
81%
Book a demo to see all comparables

For institutional investors. Book with your work email.

WebenPharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AngelJan 28, 2022
AngelJan 28, 2019
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

WebenPharma Investors

Notable investors and investment history

WebenPharma investors
InvestorRounds
Tailong InvestmentAngel
Tigeryeah CapitalAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 28, 2019

    Completed an angel funding round.

Book a demo to see all signals

For institutional investors. Book with your work email.

WebenPharma Filings

Explore SEC and related filing metadata, where available.

WebenPharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about WebenPharma's valuation, stock price, and market status.

Is WebenPharma a public or private company?

WebenPharma is a private company.

What is the current stock price of WebenPharma?

WebenPharma is a private company, so its shares have no public market price. Caplight tracks WebenPharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is WebenPharma worth (valuation)?

Valuation information for WebenPharma is not publicly available.

Can I buy WebenPharma stock?

WebenPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was WebenPharma's last funding round?

WebenPharma's most recent funding round was Angel on January 28, 2022.

Who are the main investors in WebenPharma?

Key investors in WebenPharma include Tailong Investment, Tigeryeah Capital.

Will WebenPharma IPO soon?

No public IPO plans have been announced for WebenPharma.

How can I track WebenPharma secondary market activity?

Caplight tracks bids, offers, and trades in WebenPharma's shares on secondary markets.

Firmographic Details

HeadquartersHangzhou
Year Founded2017
Last FundingJan 28, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?